ArticlePediatric cardiology2026
Clinical Outcome of Late Survivors Following the Classic Fontan Procedure.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure and multi-organ dysfunction develop insidiously in adults with a classic Fontan circulation. We evaluated late outcomes and risk factors for failing Fontan beyond 20 years after the classic Fontan procedure. Among 170 patients operated between 1978 and 1995, those surviving beyond 20 years without Fontan conversion were included. Clinical outcomes and risk factors were assessed. Sixty patients were included: tricuspid atresia in 37, double-inlet left ventricle in 14. Over 35.2 years' median follow-up, 13 (21.7%) died and 31 (51.7%) developed failing Fontan at a median of 30.8 years. Survival was lower with failing Fontan (70.2% vs. 95.2% at 35 years; P = .013) than those without. In multivariable analysis, double-inlet left ventricle (hazard ratio 2.42; P = .027) and ascites (hazard ratio 2.70; P = .007) were independent risk factors. At the last follow-up, the failing group had lower serum albumin (4.2 vs. 4.6 g/dL; P = .017) and higher N-terminal pro-B-type natriuretic peptide (774 vs. 404 pg/mL; P = .004); hepatic markers, total protein, and platelet count did not differ. After adjustment for the interval since diagnosis and exclusion of protein-losing enteropathy, only the natriuretic peptide association persisted. Peak oxygen uptake was also lower (P < .01). Late mortality and failing Fontan remained substantial beyond two decades. Double-inlet left ventricle and ascites were independent risk factors. Higher natriuretic peptide and reduced exercise capacity characterized the failing group, whereas lower albumin did not independently identify it. Regular assessment of these markers may aid surveillance.
Indexed as
Identifiers
42878803What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.